RX Securities reiterates its buy rating for the pharmaceutical company Bioarctic and raises its fair value to SEK 370, from the previous SEK 335.

Eisai is guiding for Leqembi sales of JPY 143.5 billion for the 2026/2027 fiscal year, which exceeds the research firm's previous forecast.

Consequently, RX Securities is raising its 2026 Leqembi sales forecast to USD 800 million from the previous USD 780 million. This is expected to generate royalty income for Bioarctic of SEK 741 million, up from a previous forecast of SEK 722 million.

For the full year 2026, revenues are projected at SEK 1.15 billion with a net profit of SEK 368 million.